# WHITEHAWK THERAPEUTICS, INC. (WHWK) · Edgar & Edgarette company card

> Whitehawk Therapeutics (WHWK) saw revenue fall 72.5% in FY2025 to $7 million, operating margin -1601% against a -3.8% median for pharmaceutical preparations, equity 90.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1422142 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/WHWK) · [JSON](https://www.pops4.com/boards/company/WHWK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $7M |
| Revenue growth, 1 year | -72.5% |
| Revenue growth per year | -15.5% |
| Operating margin | -1601.1% (prior year -259.6%) |
| Net margin | -288.3% |
| Operating cash flow | −$97M |
| Capital spending | $552,000 |
| Free cash flow | −$98M |
| Cash | $38M |
| Long-term debt | — |
| Total assets | $151M |
| Total equity | $136M |
| Equity ÷ assets | 90.4% |
| Return on equity | -15.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 2.98 (safe zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.17 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -1601.1% in FY2025; revenue is hard to predict: its 80% range is ±79%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $7.1M (FY2025). Experience: revenue down 72.5% on the year, down 15.5% a year over 4 years; operating margin -1601.1%, down from -259.6%. Soundness: equity 90.4% of assets, return on equity -15.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.3M and $10.8M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.1M to $12.5M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -1601.1% against a -3.8% median; growth -72.5% against 13.7%.

Range logged 2026-09-26, receipt 767a8e97553de2f2, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-10 ([filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/0001193125-26-388010-index.htm))

## Recent filings

- 8-K · filed 2026-09-10 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/0001193125-26-388010-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337933/0001193125-26-337933-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/0001193125-26-337069-index.htm)
- 8-K · filed 2026-06-12 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526269493/0001193125-26-269493-index.htm)
- 8-K · filed 2026-05-21 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/0001193125-26-234890-index.htm)
- 8-K · filed 2026-05-13 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/0001193125-26-220656-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001422142.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1422142

## Cite

POPS4, Edgar & Edgarette: WHITEHAWK THERAPEUTICS, INC. (WHWK) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/WHWK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.